The AI in drug development and clinical trial design – EORTC

EORTC – European Organisation for Research and Treatment of Cancer shared on LinkedIn:

“Join us at ENA this October in Barcelona!

Don’t miss the insightful session chaired by Rudolf Fehrmann and Caroline Chung on the current and future applications of artificial intelligence in drug development and clinical trial design.

View the programme here.

Register at the regular rate before 4 September.”

Source: EORTC/LinkedIn

Rudolf Fehrmann is a Tenure Track Adjunct Professor specializing in artificial intelligence for precision oncology at the University Medical Center Groningen (UMCG). He is a board-certified internist and medical oncologist, actively engaged in patient care, teaching, and research. As a Principal Investigator at the Cancer Research Center Groningen, he contributes to advancing cancer research. Fehrmann also serves on the Ubbo Emmius Fonds (UEF) Junior Scientific Masterclass (JSM) Talent Grant Committee.

Caroline Chung is the Director of Data Ecosystem for Data Science Development and Implementation at the Institute of Data Science for Oncology, MD Anderson Cancer Center. She also serves as Vice President and Chief Data Officer at MD Anderson Cancer Center. As a Radiation Oncologist, she is an Associate Professor in Radiation Oncology with a cross-appointment in Neuroradiology. Additionally, she chairs the WinC (Women in Cancer) and AlinC (All in Cancer) initiatives.